
High-Impact Site Clearance and Durability With Oral IL-23 Inhibition in PsO
Two-year icotrokinra data highlight sustained clearance in difficult-to-treat sites and raise important questions about IL-23–mediated disease memory.
Episodes in this series

This episode, titled ‘High-Impact Site Clearance and Durability With Oral IL-23 Inhibition in PsO,’ features panelists discussing extended data with icotrokinra in patients with psoriasis affecting high-impact sites and in adolescents with moderate-to-severe disease. Faculty review 112-week findings showing continued clearance across the scalp, genital region, hands, and feet, including areas that may require more time to reach maximal response.
The panel explains why dedicated high-impact-site studies provide information that cannot always be obtained from post hoc analyses of patients with widespread psoriasis. Patients with lower overall body surface area but moderate-to-severe localized disease represent a clinically distinct population, and historically many have been excluded from systemic therapy trials despite substantial disease burden.
The discussion then turns to long-term data from ICONIC-LEAD and the biology that may contribute to sustained response. Faculty describe reductions in CD8-positive tissue-resident memory T cells, which are believed to contribute to psoriasis recurrence in previously affected skin. Because these cells depend on IL-23 signaling for survival, IL-23–targeted therapy may influence disease persistence beyond the period of measurable drug exposure.
The panel also discusses the distinction between pharmacokinetic drug levels and longer-lasting pharmacodynamic effects, including persistence of disease control after therapy is discontinued.
In the next episode, ‘Next-Generation TYK2 Inhibitors and Speed of Response in PsO,’ panelists will discuss how quickly oral therapies work and examine head-to-head evidence differentiating newer TYK2 inhibitors.
Related to this article








